Abstract:The immune response consists of a finely-tuned program, the activation of which must be coupled with inhibitory mechanisms whenever initiated. This ensures tight control of beneficial anti-pathogen and anti-tumor responses while preserving tissue integrity, promoting tissue repair, and safeguarding against autoimmunity. A cogent example of this binary response is in the mobilization of co-stimulatory and co-inhibitory signaling in regulating the strength and type of a T-cell response. Of particular importance is the costimulatory molecule CD28 which is countered by CTLA-4. While the role of CD28 in the immune response has been thoroughly elucidated, many aspects of CTLA-4 biology remain controversial. The expression of CD28 is largely constrained to constitutive expression in T-cells and as such, teasing out its function has been somewhat simplified by a limited and specific expression profile. The expression of CTLA-4, on the other hand, while reported predominantly in T-cells, has also been described on a diverse repertoire of cells within both lymphoid and myeloid lineages as well as on the surface of tumors. Nonetheless, the function of CTLA-4 has been mostly described within the context of T-cell biology. The focus on T-cell biology may be a direct result of the high degree of amino acid sequence homology and the co-expression pattern of CD28 and CTLA-4, which initially led to the discovery of CTLA-4 as a counter receptor to CD28 (for which a T-cell-activating role had already been described). Furthermore, observations of the outsized role of CTLA-4 in T reg -mediated immune suppression and the striking phenotype of T-cell hyperproliferation and resultant disease in CTLA-4 −/− mice contribute to an appropriate T-cell-centric focus in the study of CTLA-4. Complete elucidation of CTLA-4 biology, however, may require a more nuanced understanding of its role in a context other than that of T-cells. This makes particular sense in light of the remarkable, yet limited utility of anti-CTLA-4 antibodies in the treatment of cancers and of CTLA-4-Ig in autoimmune disorders like rheumatoid arthritis. By fully deducing the biology of CTLA-4-regulated immune homeostasis, bottlenecks that hinder the widespread applicability of CTLA-4-based immunotherapies can be resolved.

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

Tumor Immune Checkpoints and Their Associated Inhibitors

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy

Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy

Understanding the cellular and molecular mechanism of anti-CTLA4 mediated tumor rejection

Elucidating CTLA-4's role in tumor immunity: a comprehensive overview of targeted antibody therapies and clinical developments

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer

Regulatory T cells in immune checkpoint blockade antitumor therapy

Targeting CTLA-4 in Cancer: Biological Insights with a Focus on Renal Cell Carcinoma

Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types

Exploring The Main Mechanisms Of Anti-Tumor And Immunotherapy-Related Adverse Events For Safer And Effective Anti-Ctla-4 Immunotherapy

CTLA-4 and PD-1 Pathways

Antibody-based Cancer Immunotherapy by Targeting Regulatory T Cells

Regulatory T cells in cancer immunosuppression — implications for anticancer therapy

Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy

CTLA-4: From mechanism to autoimmune therapy

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

The Impact of Tregs on the Anticancer Immunity and the Efficacy of Immune Checkpoint Inhibitor Therapies

Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy